Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- BullFrog AI and Sygnature Discovery have officially launched commercial sales of the BullFrog Data Networks™ platform to global biopharma clients, marking a significant milestone in AI-driven drug discovery. - The collaboration represents a revenue opportunity estimated at $15-30 million through 2028, with Sygnature's trained business development team now actively marketing the platform. - BullFrog Data Networks™ empowers researchers to analyze complex datasets for target identification, mechanism-of-action studies, patient stratification, and clinical trial optimization through an intuitive interface. - The platform aims to accelerate drug discovery by helping biopharma researchers unlock hidden relationships in biological data and improve R&D efficiency.
- BullFrog AI announced a strategic collaboration with UK-based CRO Sygnature Discovery to introduce its AI-driven BullFrog Data Networks™ platform to global biopharma clients. - The partnership is expected to generate $15-30 million in revenue for BullFrog AI through 2028 while accelerating brand recognition and user adoption. - BullFrog Data Networks™ supports critical drug discovery applications including target identification, mechanism-of-action studies, patient stratification, and clinical trial optimization. - The collaboration specifically targets small to mid-sized biopharma companies, a segment often underserved by existing bioinformatics solutions.
- BullFrog AI and Eleison Pharmaceuticals have formed a strategic collaboration to enhance the Phase 3 clinical trial of glufosfamide for pancreatic cancer using AI-powered analytics. - The partnership will leverage BullFrog Data Networks™ platform to analyze clinical data, identify predictive biomarkers, and optimize patient selection in Eleison's ongoing and future oncology trials. - The collaboration aims to accelerate the development of glufosfamide, a third-generation alkylating agent, for treating pancreatic cancer, which affects over 67,000 Americans annually with a five-year survival rate below 5%.
